References

Cancer statistics, 2009

2009 · External reference

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

10.1001/jama.299.9.1019 · 2008 · External reference

Adjuvant therapy for pancreatic cancer: a review

10.1002/cncr.23174 · 2008 · External reference

Unresolved reference

External reference

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

10.1200/jco.1998.16.9.2977 · 1998 · External reference

Clinical pharmacokinetics of capecitabine

10.2165/00003088-200140020-00002 · 2001 · External reference

Capecitabine: a review

10.1016/j.clinthera.2005.01.005 · 2005 · External reference

X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts

1999 · External reference

Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: upregulation of thymidine phosphorylase

10.1097/ppo.0b013e31813c12b8 · 2007 · External reference

Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human bxpc-3 pancreatic cancer xenografts: clinical implications of abscopal effects

10.1158/1078-0432.ccr-05-0627 · 2005 · External reference

Exploiting novel molecular targets in gastrointestinal cancers

10.3748/wjg.v13.i44.5845 · 2007 · External reference

Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α

10.1172/jci116001 · 1992 · External reference

Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique

10.1159/000093497 · 2006 · External reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

10.1200/jco.2006.07.9525 · 2007 · External reference

Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models

10.1007/s00280-005-0079-3 · 2006 · External reference

Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)

10.1158/0008-5472.can-04-3547 · 2005 · External reference

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

10.1200/jco.2001.19.13.3267 · 2001 · External reference

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SIMCYP) predicts in vivo metabolic inhibition

10.1007/s00228-007-0396-z · 2008 · External reference

Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results

10.1200/jco.2005.04.1749 · 2006 · External reference

High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers

10.1097/coc.0b013e318172d5de · 2008 · External reference

Phase I/II study of concurrent chemo-radiation in combination with erlotinib for locally advanced esophageal carcinoma

2008 · External reference

Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital

10.1200/jco.2007.15.8469 · 2008 · External reference

Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma

10.1016/s1570-0232(02)00674-8 · 2003 · External reference

Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies

10.1200/jco.2005.07.450 · 2005 · External reference

Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites

10.1016/j.jchromb.2008.05.040 · 2008 · External reference

Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry

10.1016/s1570-0232(03)00356-8 · 2003 · External reference

Unresolved reference

1982 · External reference

A program package for simulation and parameter estimation in pharmacokinetic systems

10.1016/0010-468x(79)90025-4 · 1979 · External reference

Phase I trial and biologic study of erlotinib combined with folfox-4 in patients with advanced colorectal cancer: initial results

2005 · External reference

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer

10.1016/j.clpt.2006.04.007 · 2006 · External reference

A phase I study of ekb-569 in combination with capecitabine in patients with advanced colorectal cancer

10.1158/1078-0432.ccr-08-0433 · 2008 · External reference

Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study

10.1016/j.ejca.2007.12.011 · 2008 · External reference

A phase IB dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients

10.1093/annonc/mdm452 · 2008 · External reference

Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR

10.1158/1078-0432.ccr-05-0926 · 2005 · External reference

Espac-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-fu/fa) versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinoma

2009 · External reference

Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer

10.1200/jco.2002.02.049 · 2002 · External reference

Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome

10.1200/jco.2005.02.0628 · 2005 · External reference

FDA drug approval summary: erlotinib (Tarceva) tablets

10.1634/theoncologist.10-7-461 · 2005 · External reference

Erlotinib in previously treated non-small-cell lung cancer

10.1056/nejmoa050753 · 2005 · External reference

Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer

10.1200/jco.2007.11.8521 · 2007 · External reference

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a southwest oncology group study

10.1093/annonc/mdf274 · 2002 · External reference

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

10.1038/sj.bjc.6600883 · 2003 · External reference

Phase II trial of oral rubitecan in previously treated pancreatic cancer patients

10.1634/theoncologist.10-3-183 · 2005 · External reference

Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer

10.1179/joc.2008.20.4.509 · 2008 · External reference

Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study

10.1097/01.coc.0000184682.51193.00 · 2005 · External reference

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma

10.1093/annonc/mdm441 · 2008 · External reference